Olanzapine activates hepatic mammalian target of rapamycin: New mechanistic insight into metabolic dysregulation with atypical antipsychotic drugs

Journal of Pharmacology and Experimental Therapeutics

Volumn 347, Issue 1, 2013, Pages 126-135

  Schmidt, Robin H ^a   Jokinen, Jenny D ^a   Massey, Veronica L ^a   Cameron Falkner, K ^b   Shi, Xue ^c   Yin, Xinmin ^c   Zhang, Xiang ^c   Beier, Juliane I ^a   Arteel, Gavin E ^a  

^a University of Louisville School of Medicine   (United States)

^b Department of Medicine ^*  (United States)

^c UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GLYCOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; OLANZAPINE;

ANAEROBIC GLYCOLYSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MECHANISM; ENERGY EXPENDITURE; FAT MASS; FEMALE; FOOD INTAKE; GAS CHROMATOGRAPHY; GENE EXPRESSION REGULATION; LIVER METABOLISM; LIVER WEIGHT; METABOLIC DISORDER; METABOLOMICS; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATOR GENE; SIGNAL TRANSDUCTION; TIME OF FLIGHT MASS SPECTROMETRY;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; EATING; FEMALE; INFUSION PUMPS, IMPLANTABLE; LIPID METABOLISM; LIVER; MICE; MICE, INBRED C57BL; OSMOTIC PRESSURE; TOR SERINE-THREONINE KINASES; WEIGHT GAIN;

EID: 84884618997     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.207621     Document Type: Article

References (49)

1. Albaugh VL, Vary TC, Ilkayeva O, Wenner BR, Maresca KP, Joyal JL, Breazeale S, Elich TD, Lang CH, and Lynch CJ (2012) Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents. Schizophr Bull 38:153-166.
2. Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL, Cope MB, Riley WT, Vreeland B, and Hibbeln JR, et al. (2009) Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med 36:341-350.
3. Almilaji A, Pakladok T, Guo A, Munoz C, Föller M, and Lang F (2012) Regulation of the glutamate transporter EAAT3 by mammalian target of rapamycin mTOR. Biochem Biophys Res Commun 421:159-163.
4. Andrikopoulos S, Blair AR, Deluca N, Fam BC, and Proietto J (2008) Evaluating the glucose tolerance test in mice. Am J Physiol Endocrinol Metab 295:E1323-E1332.
5. Bergheim I, Guo L, Davis MA, Lambert JC, Beier JI, Duveau I, Luyendyk JP, Roth RA, and Arteel GE (2006) Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1. Gastroenterology 130: 2099-2112.
6. Bligh EG and Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911-917.
7. Chintoh AF, Mann SW, Lam L, Lam C, Cohn TA, Fletcher PJ, Nobrega JN, Giacca A, and Remington G (2008) Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J Clin Psychopharmacol 28:494-499.
8. Coccurello R and Moles A (2010) Potential mechanisms of atypical antipsychoticinduced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther 127:210-251.
9. Cope MB, Nagy TR, Fernández JR, Geary N, Casey DE, and Allison DB (2005) Antipsychotic drug-induced weight gain: development of an animal model. Int J Obes (Lond) 29:607-614.
10. Day CP and James OF (1998) Steatohepatitis: a tale of two "hits"? Gastroenterology 114:842-845.
11. Domínguez-Jiménez JL, Puente-Gutiérrez JJ, Pelado-García EM, Cuesta-Cubillas D, and García-Moreno AM (2012) Liver toxicity due to olanzapine. Rev Esp Enferm Dig 104:617-618.
12. Ehret M, Goethe J, Lanosa M, and Coleman CI (2010) The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. J Clin Psychiatry 71:1286-1292.
13. Girault EM, Alkemade A, Foppen E, Ackermans MT, Fliers E, and Kalsbeek A (2012) Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistance. PLoS ONE 7: e43244.
14. Glavina T, Mrass D, Dodig T, Glavina G, Pranić S, and Uglešić B (2011) Blood lactate levels in patients receiving first- or second-generation antipsychotics. Croat Med J 52:41-47.
15. Goff DC, Hennen J, Lyoo IK, Tsai G, Wald LL, Evins AE, Yurgelun-Todd DA, and Renshaw PF (2002) Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry 51:493-497.
16. Grayson BE, Seeley RJ, and Sandoval DA (2013) Wired on sugar: the role of the CNS in the regulation of glucose homeostasis. Nat Rev Neurosci 14:24-37.
17. Guertin DA and Sabatini DM (2009) The pharmacology of mTOR inhibition. Sci Signal 2:pe24.
18. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, and Sabatini DM(2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11:859-871.
19. Hara K, Yonezawa K, Kozlowski MT, Sugimoto T, Andrabi K, Weng QP, Kasuga M, Nishimoto I, and Avruch J (1997) Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem 272:26457-26463.
20. Hardie DG (2007) AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8:774-785.
21. Heiskanen T, Niskanen L, Lyytikäinen R, Saarinen PI, and Hintikka J (2003) Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 64:575-579.
22. Hroudova J and Fisar Z (2010) Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers. Neuroendocrinol Lett 31:336-342.
23. Islam MM, Nautiyal M, Wynn RM, Mobley JA, Chuang DT, and Hutson SM (2010) Branched-chain amino acid metabolon: interaction of glutamate dehydrogenase with the mitochondrial branched-chain aminotransferase (BCATm). J Biol Chem 285:265-276.
24. Kapur S, VanderSpek SC, Brownlee BA, and Nobrega JN (2003) Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625-631.
25. Kim SF, Huang AS, Snowman AM, Teuscher C, and Snyder SH (2007) From the cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 104:3456-3459.
26. Kimball SR (2006) Interaction between the AMP-activated protein kinase and mTOR signaling pathways. Med Sci Sports Exerc 38:1958-1964.
27. Krause U, Bertrand L, and Hue L (2002) Control of p70 ribosomal protein S6 kinase and acetyl-CoA carboxylase by AMP-activated protein kinase and protein phosphatases in isolated hepatocytes. Eur J Biochem 269:3751-3759.
28. Laplante M and Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149:274-293.
29. Lee CT, Conde BJ, Mazlan M, Visanuyothin T, Wang A, Wong MM, Walker DJ, Roychowdhury SM, Wang H, and Tran PV (2002) Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific. J Clin Psychiatry 63:569-576.
30. Machado M, Marques-Vidal P, and Cortez-Pinto H (2006) Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 45:600-606.
31. Maher AR and Theodore G (2012) Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm 18(5, Suppl B)S1-S20.
32. Marroquin LD, Hynes J, Dykens JA, Jamieson JD, and Will Y (2007) Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol Sci 97:539-547.
33. Mathews M and Muzina DJ (2007) Atypical antipsychotics: new drugs, new challenges. Cleve Clin J Med 74:597-606.
34. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, Yang H, Hild M, Kung C, and Wilson C, et al. (2009) Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 136:521-534.
35. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, and Flegal KM (2006) Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295:1549-1555.
36. Oh KJ, Park J, Lee SY, Hwang I, Kim JB, Park TS, Lee HJ, and Koo SH (2011) Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism. Am J Physiol Endocrinol Metab 300:E624-E632.
37. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, Giral P, Grimaldi A, Opolon P, and Poynard T (2002) Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35:1485-1493.
38. Sandoval DA, Obici S, and Seeley RJ (2009) Targeting the CNS to treat type 2 diabetes. Nat Rev Drug Discov 8:386-398.
39. Skrede S, Fernø J, Vázquez MJ, Fjær S, Pavlin T, Lunder N, Vidal-Puig A, Diéguez C, Berge RK, and López M, et al. (2012) Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. Int J Neuropsychopharmacol 15: 163-179.
40. Tato I, Bartrons R, Ventura F, and Rosa JL (2011) Amino acids activate mammalian target of rapamycin complex 2 (mTORC2) via PI3K/Akt signaling. J Biol Chem 286:6128-6142.
41. Tsai G and Coyle JT (2002) Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42:165-179.
42. Tsang CK, Qi H, Liu LF, and Zheng XF (2007) Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 12:112-124.
43. van der Zwaal EM, Luijendijk MCM, Adan RAH, and la Fleur SE (2008) Olanzapineinduced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution. Eur J Pharmacol 585:130-136.
44. Warburg O, Geissler AW, and Lorenz S (1967) Uber Wachstum von Krebszellen in Medien, deren Glucose durch Galaktose ersetzt ist. Hoppe Seylers Z Physiol Chem 348:1686-1687.
45. Wei X, Shi X, Koo I, Kim S, Schmidt RH, Arteel GE, Watson WH, McClain C, and Zhang X (2013) MetPP: a computational platform for comprehensive twodimensional gas chromatography time-of-flight mass spectrometry-based metabolomics. Bioinformatics 29:1786-1792.
46. Weiden PJ, Mackell JA, and McDonnell DD (2004) Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 66:51-57.
47. Weston-Green K, Huang XF, and Deng C (2012) Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapineinduced weight gain. PLoS ONE 7:e33548.
48. Yudkoff M, Daikhin Y, Nissim I, Horyn O, Luhovyy B, Lazarow A, and Nissim I (2005) Brain amino acid requirements and toxicity: the example of leucine. J Nutr 135(6, Suppl)1531S-1538S.
49. Zhang J, Fang A, Wang B, Kim SH, Bogdanov B, Zhou Z, McClain C, and Zhang X (2011) iMatch: a retention index tool for analysis of gas chromatography-mass spectrometry data. J Chromatogr A 1218:6522-6530.